Day One Biopharmaceuticals’ (DAWN) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note issued to investors on Wednesday morning,RTT News reports. The brokerage currently has a $25.00 target price on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.32) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.47 EPS and FY2029 earnings at $1.48 EPS.

A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Needham & Company LLC dropped their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday. Bank of America lowered their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $30.57.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $6.45 on Wednesday. The company has a market capitalization of $653.73 million, a price-to-earnings ratio of -6.26 and a beta of -1.24. Day One Biopharmaceuticals has a one year low of $6.26 and a one year high of $17.14. The company’s 50-day moving average is $7.70 and its 200 day moving average is $11.10.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. As a group, research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,064 shares of company stock valued at $251,925. Company insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $866,000. Hennion & Walsh Asset Management Inc. raised its stake in Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock valued at $1,535,000 after purchasing an additional 57,601 shares during the period. MetLife Investment Management LLC lifted its holdings in Day One Biopharmaceuticals by 12.4% in the 4th quarter. MetLife Investment Management LLC now owns 34,248 shares of the company’s stock worth $434,000 after purchasing an additional 3,781 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Day One Biopharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company’s stock worth $6,785,000 after purchasing an additional 28,053 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Day One Biopharmaceuticals by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock valued at $55,336,000 after buying an additional 87,262 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.